Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer

This study will enroll women with platinum resistant high grade serous ovarian cancer.

This study is open to minorities as appropriate but is not designed to measure differences in intervention effects.

All patients must be registered for screening prior to study enrollment, however, if biomarker testing results are not required prior to enrollment to a substudy, then enrollment can proceed immediately. CCTG will advise sites when biomarker testing results are required prior to substudy enrollment.

Patients must have platinum resistant high grade serous carcinoma of ovarian, fallopian tube or peritoneal origin defined as progression within 6 months of last platinum containing chemotherapy. Histological confirmation of the original primary tumour is required.